Direct toll-like receptor 4 inhibition in Alzheimer’s disease models: a focused scoping review of inflammatory, amyloid-handling, and functional outcomes

Objective This focused scoping review evaluated whether direct toll-like receptor 4 (TLR4) inhibition, antagonism, or genetic suppression in Alzheimer’s disease (AD)-related models was associated with concordant inflammatory, amyloid-β (Aβ)-handling, and functional outcomes. Methods Original AD- or Aβ-related animal, cellular, and ex vivo studies were eligible when they directly inhibited, antagonized, or genetically suppressed TLR4 signaling using pharmacological approaches, including TAK-242/CLI-095/resatorvid, IAXO-101, RSLA, or related TLR4-targeting strategies, or genetic approaches such as TLR4 siRNA, knockdown, knockout, or loss-of-function mutation. Evidence was synthesized using a three-layer framework comprising inflammatory activation, Aβ handling, and neuronal, synaptic, or behavioral consequences. Results Direct TLR4 suppression generally attenuated target-proximal inflammatory activation, including microglial activation, pro-inflammatory mediator expression, NF-κB signaling, NLRP3 inflammasome activation, and reactive microglial phenotypes. In contrast, amyloid-related and functional outcomes were heterogeneous. Some studies reported reduced Aβ pathology, enhanced phagocytosis, synaptic protection, or cognitive improvement, whereas others showed impaired amyloid clearance, increased Aβ deposition, or worsened memory-related outcomes. APOE genotype, sex, treatment window, model system, Aβ species, and intervention type appeared to modify the direction of downstream effects. Conclusion Toll-like receptor 4 suppression relatively consistently attenuated inflammatory readouts, whereas amyloid-related and functional outcomes remained heterogeneous, supporting an exploratory, hypothesis-generating model of context-dependent inflammatory-amyloid-functional dissociation rather than a uniform therapeutic benefit.